Notably, the relationship between TRAF3IP3 and adverse outcomes in HCC patients has not been previously documented; however, the specific mechanisms underlying this relationship have not been thoroughly investigated (Pan et al., 2020). The gene discussed is TRAF3IP3; the disease is hepatocellular carcinoma.